Chemotherapy for advanced or recurrent carcinoma of the cervix.
The management of early-stage cervical cancer involves primarily surgery and/or chemoradiotherapy. When the disease spreads beyond the cervix but remains confined to the pelvis and draining lymph node basins, the mainstay of management is chemoradiotherapy. The use of primary systemic chemotherapy is related to the management of disease that has recurred or spread beyond the pelvic radiation fields. Although the optimal chemotherapy regimen remains to be determined, current protocols and the associated research to support their use are discussed in this review. Additionally, the rationale for use of chemoradiotherapy in locally advanced disease is presented.
Bloss
J D
JD
Division of Gynecologic Oncology, Ellis Fischel Cancer Center, Columbia, MO 65203, USA. blossj@health.missouri.edu
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*